Page 275 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Supplement
A
13C-dihydrouracil levels vs DOB50
400 250
13C-DHU/U ratio vs DOB50
300 200 1 0 0
200 150 100
r2 = 0 .1 7 8 00
r2 = 0 .0 1 4 P<0.0001 P=0.29
5 0
024601234
13C-dihydrouracil level (mg/l) at t=50 min 13C-DHU/U ratio at t=50 min
B
Supplementary Figure 2. Correlation between breath samples and plasma samples of the 2-13C-uracil breath test
The association between plasma samples (measured 13C-DHU/U-ratio and 13C-uracil levels at 50 minutes) and breath samples (calculated as DOB50) of the 2-13C-uracil breath test was evaluated by estimating Pearson’s correlations coefficients.
Abbreviations: vs: versus; DOB50: delta-over-baseline ratio at 50 minutes; DHU: dihydrouracil; U: uracil.
10
A
Oral uracil loading dose B 2-13C-uracil breath assay
5NS 250
4 200 3 150
2 100 150 00
NS
Supplementary Figure 3. Results of phenotyping assays separated by the occurrence of severe fluoropyrimidine-induced toxicity
Dots represent individual results. Black lines represent the median and 25th and 75th percentile of the data. All DPYD variant allele carriers were excluded from the analysis as they received initial dose reductions based on their genotype result.
Abbreviations: U: uracil; DHU: dihydrouracil; DOB50: delta-over-baseline ratio at 50 minutes; NS: not significant p-value.
273
U/DHU-ratio at 120 min
DOB50 (‰ )
DOB50
DOB50 (‰ )
No severe toxicity (N=67)
Severe toxicity (N=15)
No severe toxicity (N=63)
Severe toxicity (N=11)